NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L)…Original Article
You may also like
Dupixent (dupilumab) Approved in the U.S. as the First...
U.S. Food and Drug Administration Updates Camzyos...
FDA Grants Isturisa (osilodrostat) Expanded Indication...
Neurelis Announces FDA Approval for Immediate Use...
Mirum’s Livmarli Now FDA Approved in Tablet...
FDA Grants Interchangeable Designation to Yuflyma...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.